Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Phase II trial of combination therapy for advanced breast cancer underway
November 24th, 2005
OncoGenex Technologies Inc. announced that the first patient has been treated in a phase II clinical trial of OGX-011 in combination with docetaxel in patients with advanced breast cancer. OGX-011 is a second-generation antisense drug designed to specifically inhibit the production of clusterin, a cell-survival protein associated with resistance to standard anticancer treatments. This clinical trial is designed to assess the safety and efficacy of OGX-011 in combination with docetaxel in women with metastatic or locally advanced breast cancer. OncoGenex is developing OGX-011 in collaboration with Isis Pharmaceuticals Inc. (ISIS). Increased clusterin...
Source: Women's Health Weekly (2005-11-24)
|
